{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T00:45:07Z","timestamp":1790210707487,"version":"4.1.0"},"reference-count":88,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,4,14]],"date-time":"2023-04-14T00:00:00Z","timestamp":1681430400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000774","name":"Defense Threat Reduction Agency","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000774","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Cell. Infect. Microbiol."],"abstract":"<jats:p>The rise of antimicrobial-resistant bacterial infections is a crucial health concern in the 21st century. In particular, antibiotic-resistant <jats:italic>Pseudomonas aeruginosa<\/jats:italic> causes difficult-to-treat infections associated with high morbidity and mortality. Unfortunately, the number of effective therapeutic interventions against antimicrobial-resistant <jats:italic>P. aeruginosa<\/jats:italic> infections continues to decline. Therefore, discovery and development of alternative treatments are necessary. Here, we present pre-clinical efficacy studies on an anti-<jats:italic>P. aeruginosa<\/jats:italic> therapeutic monoclonal antibody. Using hybridoma technology, we generated a monoclonal antibody and characterized its binding to <jats:italic>P. aeruginosa in vitro<\/jats:italic> using ELISA and fluorescence correlation spectroscopy. We also characterized its function <jats:italic>in vitro<\/jats:italic> and <jats:italic>in vivo<\/jats:italic> against <jats:italic>P. aeruginosa<\/jats:italic>. The anti-<jats:italic>P. aeruginosa<\/jats:italic> antibody (WVDC-5244) bound <jats:italic>P. aeruginosa<\/jats:italic> clinical strains of various serotypes <jats:italic>in vitro<\/jats:italic>, even in the presence of alginate exopolysaccharide. In addition, WVDC-5244 induced opsonophagocytic killing of <jats:italic>P. aeruginosa in vitro<\/jats:italic> in J774.1 murine macrophage, and complement-mediated killing. In a mouse model of acute pneumonia, prophylactic administration of WVDC-5244 resulted in an improvement of clinical disease manifestations and reduction of <jats:italic>P. aeruginosa<\/jats:italic> burden in the respiratory tract compared to the control groups. This study provides promising pre-clinical efficacy data on a new monoclonal antibody with therapeutic potential for <jats:italic>P. aeruginosa<\/jats:italic> infections.<\/jats:p>","DOI":"10.3389\/fcimb.2023.1117844","type":"journal-article","created":{"date-parts":[[2023,4,14]],"date-time":"2023-04-14T05:21:30Z","timestamp":1681449690000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":18,"title":["Development of an anti-Pseudomonas aeruginosa therapeutic monoclonal antibody WVDC-5244"],"prefix":"10.3389","volume":"13","author":[{"given":"Alexander M.","family":"Horspool","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emel","family":"Sen-Kilic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aaron C.","family":"Malkowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott L.","family":"Breslow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margalida","family":"Mateu-Borras","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew S.","family":"Hudson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mason A.","family":"Nunley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sean","family":"Elliott","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Krishanu","family":"Ray","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Greg A.","family":"Snyder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah Jo","family":"Miller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason","family":"Kang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine B.","family":"Blackwood","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kelly L.","family":"Weaver","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William T.","family":"Witt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annalisa B.","family":"Huckaby","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gage M.","family":"Pyles","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tammy","family":"Clark","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saif","family":"Al Qatarneh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George K.","family":"Lewis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F. Heath","family":"Damron","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariette","family":"Barbier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,4,14]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1111\/j.1365-3083.1994.tb03416.x","article-title":"Opsonophagocytic activity induced by chimeric antibodies of the four human IgG subclasses with or without help from complement","volume":"39","author":"Aase","year":"1994","journal-title":"Scand. J. Immunol."},{"key":"B2","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1016\/j.celrep.2019.08.074","article-title":"Stoichiometric analyses of soluble CD4 to native-like HIV-1 envelope by single-molecule fluorescence spectroscopy","volume":"29","author":"Agrawal","year":"2019","journal-title":"Cell Rep."},{"key":"B3","doi-asserted-by":"publisher","first-page":"629.e1","DOI":"10.1016\/j.cmi.2018.08.004","article-title":"Phase 1 study of MEDI3902, an investigational anti\u2013Pseudomonas aeruginosa PcrV and psl bispecific human monoclonal antibody, in healthy adults","volume":"25","author":"Ali","year":"2019","journal-title":"Clin. Microbiol. Infect."},{"key":"B4","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1128\/iai.49.2.281-285.1985","article-title":"Opsonophagocytic killing activity of rabbit antibody to Pseudomonas aeruginosa mucoid exopolysaccharide","volume":"49","author":"Ames","year":"1985","journal-title":"Infect. Immun."},{"key":"B5","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1093\/clinids\/21.1.150","article-title":"Return tothe past: The case for antibody-based therapies in infectious diseases","volume":"21","author":"Arturo","year":"1995","journal-title":"Clin. Infect. Dis."},{"key":"B6","doi-asserted-by":"publisher","first-page":"6339","DOI":"10.1128\/IAI.00982-06","article-title":"Human monoclonal antibodies directed against toxins a and b prevent clostridium difficile-induced mortality in hamsters","volume":"74","author":"Babcock","year":"2006","journal-title":"Infect. Immun."},{"key":"B7","doi-asserted-by":"publisher","first-page":"2941","DOI":"10.1128\/jvi.63.7.2941-2950.1989","article-title":"Neutralization epitopes of the f glycoprotein of respiratory syncytial virus: effect of mutation upon fusion function","volume":"63","author":"Beeler","year":"1989","journal-title":"J. Virol."},{"key":"B8","article-title":"Ueber das Zustandekommen der Diphtherie-Immunit\u00e4t und der Tetanus-Immunit\u00e4t bei Thieren","volume-title":"Deutschen Medicinischen Wochenschrift","author":"Behring","year":"1890"},{"key":"B9","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12890-016-0339-5","article-title":"Cystic fibrosis lung environment and Pseudomonas aeruginosa infection","volume":"16","author":"Bhagirath","year":"2016","journal-title":"BMC Pulm. Med"},{"key":"B10","doi-asserted-by":"publisher","first-page":"5640","DOI":"10.1182\/blood-2012-01-380121","article-title":"Properties of mouse and human IgG receptors and their contribution to disease models","volume":"119","author":"Bruhns","year":"2012","journal-title":"Blood"},{"key":"B11","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1086\/318075","article-title":"Longitudinal assessment of Pseudomonas aeruginosa in young children with cystic fibrosis","volume":"183","author":"Burns","year":"2001","journal-title":"J. Infect. Dis."},{"key":"B12","doi-asserted-by":"publisher","first-page":"1695","DOI":"10.1128\/AAC.38.8.1695","article-title":"Serum therapy revisited: Animal models of infection and development of passive antibody therapy","volume":"38","author":"Casadevall","year":"1994","journal-title":"Antimicrob. Agents Chemother."},{"key":"B13","article-title":"Antibiotic resistance threats in the united states","year":"2019"},{"key":"B14","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1128\/jb.00595-18","article-title":"Genomic and phenotypic diversity among ten laboratory isolates of Pseudomonas aeruginosa PAO1","volume":"201","author":"Chandler","year":"2018","journal-title":"J. Bacteriol."},{"key":"B15","doi-asserted-by":"publisher","first-page":"S377","DOI":"10.1093\/ofid\/ofaa439.829","article-title":"635. efficacy, pharmacokinetics (PK), and safety profile of MEDI3902, an anti- Pseudomonas aeruginosa bispecific human monoclonal antibody in mechanically ventilated intensive care unit patients; results of the phase 2 EVADE study conducted by the","volume":"7","author":"Chastre","year":"2020","journal-title":"Open Forum Infect. Dis."},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1038\/nmicrobiol.2016.3","article-title":"When the drugs don\u2019t work","volume":"1","author":"Dean","year":"2016","journal-title":"Pharm. News"},{"key":"B17","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1016\/S0966-842X(00)88974-X","article-title":"Pseudomonas aeruginosa, mucoidy and the chronic infection phenotype in cystic fibrosis","volume":"3","author":"Deretic","year":"1995","journal-title":"Trends Microbiol."},{"key":"B18","doi-asserted-by":"publisher","first-page":"21065","DOI":"10.1073\/pnas.1307862110","article-title":"Evolutionary genomics of epidemic and nonepidemic strains of Pseudomonas aeruginosa","volume":"110","author":"Dettman","year":"2013","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"B19","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1084\/jem.20120033","article-title":"Identification of broadly protective human antibodies to Pseudomonas aeruginosa exopolysaccharide psl by phenotypic screening","volume":"209","author":"DiGiandomenico","year":"2012","journal-title":"J. Exp. Med"},{"key":"B20","doi-asserted-by":"publisher","first-page":"262ra155 LP","DOI":"10.1126\/scitranslmed.3009655","article-title":"A multifunctional bispecific antibody protects against Pseudomonas aeruginosa","volume":"6","author":"DiGiandomenico","year":"2014","journal-title":"Sci. Transl. Med."},{"key":"B21","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1016\/S0305-4179(02)00024-4","article-title":"Frequency of Pseudomonas aeruginosa serotypes in burn wound infections and their resistance to antibiotics","volume":"28","author":"Estahbanati","year":"2002","journal-title":"Burns"},{"key":"B22","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1097\/COH.0000000000000154","article-title":"History of passive antibody administration for prevention and treatment of infectious diseases","volume":"10","author":"Graham","year":"2015","journal-title":"Curr. Opin. HIV AIDS"},{"key":"B23","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.tibtech.2018.05.014","article-title":"The increasingly human and profitable monoclonal antibody market","volume":"37","author":"Grilo","year":"2019","journal-title":"Trends Biotechnol."},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2164-15-318","article-title":"Pseudomonas aeruginosa clinical and environmental isolates constitute a single population with high phenotypic diversity","volume":"15","author":"Grosso-Becerra","year":"2014","journal-title":"BMC Genomics"},{"key":"B25","doi-asserted-by":"publisher","first-page":"1272","DOI":"10.1001\/jama.1954.02950010023009","article-title":"Evaluation of red cross gamma globulin as a prophylactic agent for poliomyelitis. IV. final report of results based on clinical diagnoses","volume":"151","author":"Hammon","year":"1954","journal-title":"J. Am. Med. Assoc."},{"key":"B26","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1159\/000491439","article-title":"Complement and bacterial infections: From molecular mechanisms to therapeutic applications","volume":"10","author":"Heesterbeek","year":"2018","journal-title":"J. Innate Immun."},{"key":"B27","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1126\/science.29.737.241","article-title":"Opsonins and other antibodies","volume":"29","author":"Hektoen","year":"1909","journal-title":"Science"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1128\/microbiolspec.AID-0026-2014","article-title":"History and practice: Antibodies in infectious diseases","volume":"3","author":"Hey","year":"2015","journal-title":"Microbiol Spectr."},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0123448","article-title":"Functional advantages of Porphyromonas gingivalis vesicles","volume":"10","author":"Ho","year":"2015","journal-title":"PLoS One"},{"key":"B30","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1099\/00222615-31-2-119","article-title":"Ecology of Pseudomonas aeruginosa in patients with cystic fibrosis","author":"Horrevorts","year":"2012"},{"key":"B31","doi-asserted-by":"publisher","first-page":"9873","DOI":"10.1038\/s41598-018-28042-4","article-title":"Reciprocal cross-species induction of outer membrane vesicle biogenesis via secreted factors","volume":"8","author":"Horspool","year":"2018","journal-title":"Sci. Rep."},{"key":"B32","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1128\/mBio.00199-10","article-title":"Parallel evolution in Pseudomonas aeruginosa over 39,000 generations In vivo","volume":"1","author":"Huse","year":"2010","journal-title":"MBio"},{"key":"B33","doi-asserted-by":"publisher","first-page":"14339","DOI":"10.1073\/pnas.2036282100","article-title":"Comprehensive transposon mutant library of Pseudomonas aeruginosa","volume":"100","author":"Jacobs","year":"2003","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"B34","doi-asserted-by":"publisher","first-page":"649","DOI":"10.3109\/00365548709117200","article-title":"Human IgG antibodies to Pseudomonas aeruginosa core lipopolysaccharide determinants are detected in chronic but not acute pseudomonas infection","volume":"19","author":"Jacobson","year":"1987","journal-title":"Scand. J. Infect. Dis."},{"key":"B35","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fmicb.2017.01053","article-title":"Outer membrane vesicles (OMVs) of gram-negative bacteria: A perspective update","volume":"8","author":"Jan","year":"2017","journal-title":"Front. Microbiol."},{"key":"B36","first-page":"202","article-title":"Use of concentrated human serum gamma-globulin in the prevention and attenuation of measles","volume":"21","author":"Janeway","year":"1945","journal-title":"Bull. N. Y. Acad. Med."},{"key":"B37","doi-asserted-by":"publisher","first-page":"1215","DOI":"10.1086\/514115","article-title":"Development of a humanized monoclonal antibody (MEDI-493) with potent in vitro and in vivo activity against respiratory syncytial virus","volume":"176","author":"Johnson","year":"1997","journal-title":"J. Infect. Dis."},{"key":"B38","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1093\/cid\/ciy577","article-title":"Bezlotoxumab","volume":"68","author":"Johnson","year":"2019","journal-title":"Clin. Infect. Dis."},{"key":"B39","doi-asserted-by":"publisher","first-page":"20441","DOI":"10.1073\/pnas.1013827107","article-title":"Antibodies protect against intracellular bacteria by fc receptor-mediated lysosomal targeting","volume":"107","author":"Joller","year":"2010","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"B40","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1093\/jac\/40.5.615","article-title":"Natural release of virulence factors in membrane vesicles by Pseudomonas aeruginosa and the effect of aminoglycoside antibiotics on their release","author":"Kadurugamuwa","year":"1997","journal-title":"J. Antimicrob. Chemother."},{"key":"B41","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1128\/mBio.00117-17","article-title":"Remembering Emil Von Behring: From tetanus treatment to antibody cooperation with phagocytes","volume":"8","author":"Kaufmann","year":"2017","journal-title":"MBio"},{"key":"B42","doi-asserted-by":"publisher","first-page":"5300","DOI":"10.1128\/IAI.00501-09","article-title":"Inescapable need for neutrophils as mediators of cellular innate immunity to acute Pseudomonas aeruginosa pneumonia","volume":"77","author":"Koh","year":"2009","journal-title":"Infect. Immun."},{"key":"B43","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1038\/256495a0","article-title":"Continuous cultures of fused cells secreting antibody of predefined specificity","volume":"256","author":"K\u00f6hler","year":"1975","journal-title":"Nature"},{"key":"B44","doi-asserted-by":"publisher","first-page":"CD013825","DOI":"10.1002\/14651858.CD013825","article-title":"SARS-CoV-2-neutralising monoclonal antibodies for treatment of COVID-19","volume":"9","author":"Kreuzberger","year":"2021","journal-title":"Cochrane Database Syst. Rev."},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.3389\/fmicb.2011.00118","article-title":"Genetic and functional diversity of Pseudomonas aeruginosa lipopolysaccharide","volume":"2","author":"Lam","year":"2011","journal-title":"Front. Microbiol."},{"key":"B46","doi-asserted-by":"publisher","first-page":"1133","DOI":"10.1016\/j.micinf.2011.07.011","article-title":"Innate immune responses to Pseudomonas aeruginosa infection","volume":"13","author":"Lavoie","year":"2011","journal-title":"Microbes Infect"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02565-17","article-title":"MEDI3902 correlates of protection against severe Pseudomonas aeruginosa pneumonia in a rabbit acute pneumonia model","volume":"62","author":"Le","year":"2018","journal-title":"Antimicrob. Agents Chemother."},{"key":"B48","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1016\/S0928-8244(99)00102-9","article-title":"Human anti-Pseudomonas aeruginosa outer membrane proteins IgG cross-protective against infection with heterologous immunotype strains of p. aeruginosa","volume":"25","author":"Lee","year":"1999","journal-title":"FEMS Immunol. Med. Microbiol."},{"key":"B49","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1016\/j.amsu.2014.09.001","article-title":"The history of monoclonal antibody development - progress, remaining challenges and future innovations","volume":"3","author":"Liu","year":"2014","journal-title":"Ann. Med. Surg."},{"key":"B50","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1038\/nri.2017.106","article-title":"Beyond binding: antibody effector functions in infectious diseases","volume":"18","author":"Lu","year":"2018","journal-title":"Nat. Rev. Immunol."},{"key":"B51","doi-asserted-by":"publisher","first-page":"1198","DOI":"10.1056\/NEJMoa1306801","article-title":"Multistate point-prevalence survey of health care\u2013associated infections","volume":"370","author":"Magill","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"B52","doi-asserted-by":"publisher","first-page":"e00138","DOI":"10.1128\/CMR.00138-18","article-title":"Cystic fibrosis and Pseudomonas aeruginosa: the host-microbe interface","volume":"32","author":"Malhotra","year":"2019","journal-title":"Clin. Microbiol. Rev."},{"key":"B53","doi-asserted-by":"publisher","first-page":"3738","DOI":"10.1172\/JCI36452","article-title":"Fc g RIV is a mouse IgE receptor that resembles macrophage fc e RI in humans and promotes IgE-induced lung inflammation find the latest version: Fc \u03b3 RIV is a mouse IgE receptor that resembles macrophage fc \u03f5 RI in humans and promotes IgE-induced lung in","author":"Mancardi","year":"2008"},{"key":"B54","doi-asserted-by":"publisher","first-page":"1349","DOI":"10.1099\/13500872-145-6-1349","article-title":"Mucoid conversion of Pseudomonas aeruginosa by hydrogen peroxide: a mechanism for virulence activation in the cystic fibrosis lung","volume":"145","author":"Mathee","year":"1999","journal-title":"Microbiology"},{"key":"B55","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1089\/sur.2018.233","article-title":"Progress toward the elusive Pseudomonas aeruginosa vaccine","volume":"19","author":"Merakou","year":"2018","journal-title":"Surg. Infect. (Larchmt)."},{"key":"B56","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1111\/j.0300-9475.2004.01362.x","article-title":"The four mouse IgG isotypes differ extensively in bactericidal and opsonophagocytic activity when reacting with the P1.16 epitope on the outer membrane PorA protein of neisseria meningitidis","volume":"59","author":"Michaelsen","year":"2004","journal-title":"Scand. J. Immunol."},{"key":"B57","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1002\/ppul.22890","article-title":"Anti-PcrV antibody in cystic fibrosis: a novel approach targeting Pseudomonas aeruginosa airway infection","volume":"49","author":"Milla","year":"2014","journal-title":"Pediatr. Pulmonol."},{"key":"B58","first-page":"1277","article-title":"Monoclonal antibodies provide protection against ocular Pseudomonas aeruginosa infection","volume":"29","author":"Moon","year":"1988","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"B59","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1038\/nrd4770","article-title":"Antibacterial antibodies gain traction","volume":"14","author":"Morrison","year":"2015","journal-title":"Nat. Rev. Drug Discovery"},{"key":"B60","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1186\/s12879-020-4811-8","article-title":"Multi-drug resistance of blood stream, urinary tract and surgical site nosocomial infections of acinetobacter baumannii and Pseudomonas aeruginosa among patients hospitalized at felegehiwot referral hospital, Northwest Ethiopia: a cross-sectional study","volume":"20","author":"Motbainor","year":"2020","journal-title":"BMC Infect. Dis."},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1128\/mSphere.00397-17","article-title":"A new take on an old remedy: generating antibodies against multidrug-resistant Gram-negative bacteria in a postantibiotic world","volume":"2","author":"Motley","year":"2017","journal-title":"mSphere"},{"key":"B62","doi-asserted-by":"publisher","first-page":"1188","DOI":"10.1056\/NEJMc2113505","article-title":"Antibody use during an outbreak of Ebola virus disease in the democratic republic of Congo, 2020","volume":"386","author":"Mulangu","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"B63","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1038\/307136a0","article-title":"Correlation between segmental flexibility and effector function of antibodies","volume":"307","author":"Oi","year":"1984","journal-title":"Nature"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-017-00576-7","article-title":"An engineered bispecific DNA-encoded IgG antibody protects against Pseudomonas aeruginosa in a pneumonia challenge model","volume":"8","author":"Patel","year":"2017","journal-title":"Nat. Commun"},{"key":"B65","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1016\/j.jaci.2016.09.023","article-title":"Update on the use of immunoglobulin in human disease: A review of evidence","volume":"139","author":"Perez","year":"2017","journal-title":"J. Allergy Clin. Immunol."},{"key":"B66","doi-asserted-by":"publisher","first-page":"798","DOI":"10.1056\/NEJM198709243171303","article-title":"Opsonophagocytic killing antibody to Pseudomonas aeruginosa mucoid exopolysaccharide in older noncolonized patients with cystic fibrosis","volume":"317","author":"Pier","year":"1987","journal-title":"N. Engl. J. Med."},{"key":"B67","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1038\/257393a0","article-title":"Phagocytosis and cytolysis by a macrophage tumour and its cloned cell line","volume":"257","author":"Ralph","year":"1975","journal-title":"Nature"},{"key":"B68","doi-asserted-by":"publisher","first-page":"1795","DOI":"10.1128\/JVI.03048-13","article-title":"Antigenic properties of the HIV envelope on virions in solution","volume":"88","author":"Ray","year":"2014","journal-title":"J. Virol."},{"key":"B69","doi-asserted-by":"publisher","first-page":"3614","DOI":"10.1128\/JB.184.13.3614-3622.2002","article-title":"Genetic variation at the O-antigen biosynthetic locus in Pseudomonas aeruginosa","volume":"184","author":"Raymond","year":"2002","journal-title":"J. Bacteriol"},{"key":"B70","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1172\/JCI108102","article-title":"Specificity of opsonic antibodies to enhance phagocytosis of Pseudomonas aeruginosa by human alveolar macrophages","volume":"56","author":"Reynolds","year":"1975","journal-title":"J. Clin. Invest."},{"key":"B71","doi-asserted-by":"publisher","first-page":"2117","DOI":"10.1007\/s40265-021-01635-6","article-title":"The epidemiology and pathogenesis and treatment of Pseudomonas aeruginosa infections: An update","volume":"81","author":"Reynolds","year":"2021","journal-title":"Drugs"},{"key":"B72","doi-asserted-by":"publisher","first-page":"1209","DOI":"10.1164\/rccm.200408-1044SO","article-title":"Pathogen-host interactions in Pseudomonas aeruginosa pneumonia","volume":"171","author":"Sadikot","year":"2005","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"B73","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fimmu.2019.01296","article-title":"Conceptual approaches to modulating antibody effector functions and circulation half-life","volume":"10","author":"Saunders","year":"2019","journal-title":"Front. Immunol."},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.1186\/2052-0492-2-10","article-title":"The molecular mechanism of acute lung injury caused by Pseudomonas aeruginosa: From bacterial pathogenesis to host response","volume":"2","author":"Sawa","year":"2014","journal-title":"J. Intensive Care"},{"key":"B75","doi-asserted-by":"publisher","first-page":"e00297","DOI":"10.1128\/mBio.00297-11","article-title":"A bilayer-couple model of bacterial outer membrane vesicle biogenesis","volume":"3","author":"Schertzer","year":"2012","journal-title":"MBio"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.02497","article-title":"Intranasal peptide-based fpva-KLH conjugate vaccine protects mice from Pseudomonas aeruginosa acute murine pneumonia","volume":"10","author":"Sen-Kilic","year":"2019","journal-title":"Front. Immunol"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.1128\/IAI.00451-20","article-title":"Defining the mechanistic correlates of protection conferred by whole-cell vaccination against Pseudomonas aeruginosa acute murine pneumonia","volume":"89","author":"Sen-Kilic","year":"2021","journal-title":"Infect. Immun."},{"key":"B78","doi-asserted-by":"publisher","first-page":"5272","DOI":"10.1128\/IAI.00546-06","article-title":"Extensive genomic plasticity in Pseudomonas aeruginosa revealed by identification and distribution studies of novel genes among clinical isolates","volume":"74","author":"Shen","year":"2006","journal-title":"Infect. Immun."},{"key":"B79","doi-asserted-by":"publisher","first-page":"3692","DOI":"10.1073\/pnas.1800043115","article-title":"Monoclonal antibody targeting the \u03b2-barrel assembly machine of escherichia coli is bactericidal","volume":"115","author":"Storek","year":"2018","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"B80","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41598-018-34020-7","article-title":"Comparative genomics of clinical strains of Pseudomonas aeruginosa strains isolated from different geographic sites","volume":"8","author":"Subedi","year":"2018","journal-title":"Sci. Rep."},{"key":"B81","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1172\/jci.insight.121737","article-title":"Mouse model of gram-negative prosthetic joint infection reveals therapeutic targets","volume":"3","author":"Thompson","year":"2018","journal-title":"JCI Insight"},{"key":"B82","doi-asserted-by":"publisher","first-page":"1782","DOI":"10.1128\/JCM.00349-16","article-title":"Application of whole-genome sequencing data for o-specific antigen analysis and in silico serotyping of Pseudomonas aeruginosa isolates","volume":"54","author":"Thrane","year":"2016","journal-title":"J. Clin. Microbiol."},{"key":"B83","doi-asserted-by":"publisher","first-page":"1","DOI":"10.12688\/f1000research.19509.1","article-title":"Emerging therapies against infections with Pseudomonas aeruginosa","volume":"8","author":"T\u00fcmmler","year":"2019","journal-title":"F1000Research"},{"key":"B84","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1016\/s1357-4310(99)01506-3","article-title":"Cystic fibrosis: an inherited susceptibility to bacterial respiratory infections","volume":"5","author":"T\u00fcmmler","year":"1999","journal-title":"Mol. Med. Today"},{"key":"B85","doi-asserted-by":"publisher","first-page":"1288","DOI":"10.1017\/ice.2016.174","article-title":"Antimicrobial-resistant pathogens associated with healthcare-associated infections: Summary of data reported to the national healthcare safety network at the centers for disease control and prevention, 2011-2014","volume":"37","author":"Weiner","year":"2016","journal-title":"Infect. Control Hosp. Epidemiol."},{"key":"B86","doi-asserted-by":"publisher","first-page":"828","DOI":"10.1136\/bjo.68.11.828","article-title":"Topical immunotherapy for pseudomonas keratitis in rabbits: Use of antilipopolysaccharide plasma","volume":"68","author":"Welsh","year":"1984","journal-title":"Br. J. Ophthalmol."},{"key":"B87","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1128\/IAI.74.2.975-983.2006","article-title":"A live-attenuated Pseudomonas aeruginosa vaccine elicits outer membrane protein-specific active and passive protection against corneal infection","volume":"74","author":"Zaidi","year":"2006","journal-title":"Infect. Immun."},{"key":"B88","doi-asserted-by":"publisher","DOI":"10.3390\/antibiotics9040155","article-title":"Monoclonal antibodies as an antibacterial approach against bacterial pathogens","volume":"9","author":"Zurawski","year":"2020","journal-title":"Antibiotics"}],"container-title":["Frontiers in Cellular and Infection Microbiology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcimb.2023.1117844\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,14]],"date-time":"2023-04-14T05:21:38Z","timestamp":1681449698000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcimb.2023.1117844\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,14]]},"references-count":88,"alternative-id":["10.3389\/fcimb.2023.1117844"],"URL":"https:\/\/doi.org\/10.3389\/fcimb.2023.1117844","relation":{},"ISSN":["2235-2988"],"issn-type":[{"value":"2235-2988","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,4,14]]},"article-number":"1117844"}}